바이오엔지니어링 단백질 및 효소 시장 : 전략적 인사이트와 예측(2026-2031년)

The Bioengineered Proteins and Enzymes market is expected to grow at a CAGR of 10.8%, reaching USD 11.5 billion in 2031 from USD 6.9 billion in 2026.

The global bioengineered proteins and enzymes market is positioned at the core of modern biotechnology, driven by rapid advancements in synthetic biology, recombinant DNA technology, and precision biomanufacturing. These engineered biomolecules are increasingly used across pharmaceuticals, industrial processing, agriculture, and food production. The market is benefiting from the growing demand for biologics, targeted therapies, and sustainable industrial solutions. In parallel, the integration of artificial intelligence and gene editing technologies is accelerating protein design and production efficiency. As industries shift toward high-performance, eco-friendly alternatives to conventional chemicals, bioengineered proteins and enzymes are becoming critical components of next-generation manufacturing and healthcare systems.

Market Drivers

A major driver is the rising demand for advanced biologics and targeted therapies. Increasing prevalence of chronic diseases such as cancer, autoimmune disorders, and metabolic conditions is driving the adoption of engineered proteins including monoclonal antibodies, cytokines, and therapeutic enzymes. These biomolecules offer higher specificity and improved clinical outcomes compared to traditional treatments.

Technological advancements in protein engineering and synthetic biology are further accelerating market growth. Innovations such as CRISPR gene editing, AI-based protein modeling, and directed evolution techniques are enabling faster and more precise development of customized proteins with enhanced stability and functionality.

The expansion of industrial biotechnology applications also contributes significantly. Engineered enzymes are increasingly replacing chemical catalysts in industries such as food processing, detergents, biofuels, and agriculture due to their efficiency, lower energy requirements, and environmental benefits. Additionally, growing emphasis on sustainability and green chemistry is encouraging industries to adopt enzyme-based processes that reduce waste and emissions.

Market Restraints

The market faces constraints related to high research and development costs. Developing bioengineered proteins and enzymes requires advanced laboratories, skilled personnel, and complex bioprocessing infrastructure, leading to significant capital investment and long development timelines.

Regulatory complexity is another key challenge, particularly for therapeutic proteins. Stringent approval processes, extensive clinical trials, and biosafety requirements increase time-to-market and compliance costs.

Manufacturing scalability also remains a concern. Large-scale production of consistent, high-quality proteins involves technical challenges such as yield optimization, contamination control, and batch variability, which can impact commercialization efficiency.

Technology and Segment Insights

The market is segmented by product type, application, and production technology. Recombinant proteins represent a dominant segment, driven by their widespread use in therapeutics and research applications. These include monoclonal antibodies, hormones, and cytokines used in treating complex diseases.

By application, the biopharmaceutical sector leads the market due to high investment in drug discovery, biologics manufacturing, and precision medicine. Industrial applications are also expanding rapidly, particularly in food processing, biofuels, and textiles, where engineered enzymes improve process efficiency and sustainability.

Technologically, platforms such as microbial expression systems, mammalian cell cultures, and emerging cell-free synthesis systems are driving innovation. AI-assisted protein design and high-throughput screening are further enhancing development speed and product performance.

Competitive and Strategic Outlook

The competitive landscape is characterized by the presence of global biotechnology and chemical companies focusing on innovation and portfolio expansion. Key players such as Thermo Fisher Scientific, Merck KGaA, Bio-Techne Corporation, GenScript Biotech, and BASF are investing in advanced protein engineering platforms and expanding their biomanufacturing capabilities.

Strategic initiatives include partnerships with research institutions, development of AI-driven protein design tools, and expansion into high-growth application areas such as personalized medicine and industrial biotechnology. Companies are also focusing on scalable production technologies to address growing global demand.

Conclusion

The global bioengineered proteins and enzymes market is expected to witness robust growth, supported by technological advancements, increasing demand for biologics, and expanding industrial applications. While high costs, regulatory hurdles, and scalability challenges remain, continuous innovation in synthetic biology and biomanufacturing will drive long-term market expansion.

Key Benefits of this Report

• Insightful Analysis: Gain detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2025 and forecast data from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations
• 3.8. Product Pipeline Analysis
• 3.9. Incidence and Prevalence Analysis
• 3.10. Patent Analysis

4. TECHNOLOGICAL OUTLOOK

5. BIOENGINEERED PROTEINS AND ENZYMES MARKET BY PRODUCT TYPE

• 5.1. Introduction
• 5.2. Recombinant Proteins
• 5.3. Therapeutic Proteins
• 5.4. Industrial Enzymes
• 5.5. Diagnostic Enzymes
• 5.6. Specialty Proteins
• 5.7. Biosimilars

6. BIOENGINEERED PROTEINS AND ENZYMES MARKET BY APPLICATION

• 6.1. Introduction
• 6.2. Biopharmaceuticals
• 6.3. Diagnostics & Research
• 6.4. Food & Beverages
• 6.5. Animal Feed & Nutrition
• 6.6. Biofuels & Energy
• 6.7. Detergents & Textiles
• 6.8. Agriculture & Crop Protection
• 6.9. Cosmetics & Personal Care
• 6.10. Environmental Biotechnology

7. BIOENGINEERED PROTEINS AND ENZYMES MARKET BY END-USER

• 7.1. Introduction
• 7.2. Pharmaceutical & Biotechnology Companies
• 7.3. Contract Research and Manufacturing Organizations (CROs/CDMOs)
• 7.4. Academic and Research Institutions
• 7.5. Industrial Manufacturers
• 7.6. Food & Beverage Manufacturers
• 7.7. Agriculture & Livestock Firms

8. BIOENGINEERED PROTEINS AND ENZYMES MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. United Kingdom
  • 8.4.2. Germany
  • 8.4.3. France
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Thermo Fisher Scientific Inc.
• 10.2. Merck KGaA
• 10.3. Bio-Techne Corporation
• 10.4. Abcam plc
• 10.5. GenScript Biotech Corporation
• 10.6. Sino Biological Inc.
• 10.7. Novonesis
• 10.8. Codexis, Inc.
• 10.9. BASF SE
• 10.10. Advanced Enzyme Technologies Ltd.

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key benefits for the stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations